DeutschNewstral
Article
bizjournals.com on 2021-06-09 14:10
How RTP plays critical role for Biogen's blockbuster Alzheimer's drug
Related news
- How RTP plays critical role for Biogen's blockbuster Alzheimer's drugbizjournals.com
- Biogen's Alzheimer's drug wins FDA approvalbizjournals.com
- Medicare severely restricts Biogen's Alzheimer's drug coveragebizjournals.com
- Details behind Biogen's buy of Eisai's RTP facilities unveiledbizjournals.com
- BThe $56,000 Price of Biogen's Alzheimer's Drug Could Backfire4 minbarrons.com
- Biogen's other Alzheimer's drug fails in late-stage trialbizjournals.com
- Biogen's CEO made $17.7M last year despite Alzheimer's drug woesbizjournals.com
- After Biogen's big Alzheimer's drug data reveal, observers remain dividedbizjournals.com
FDA approval of Biogen's Alzheimer's drug leaves some 'disappointed'Fox News- BMedicare Will Limit Coverage of Biogen's Alzheimer's Drug2 min readbarrons.com
- Analysts wary of Biogen's strategy as earnings, Alzheimer's data loombizjournals.com
- For Alzheimer's patient advocates, Biogen's drug approval opens the doorbizjournals.com
Biogen's Alzheimer's drug cited as Medicare premium jumps by $21.60WRAL- BBJ Live: Why all eyes will be on Biogen's Alzheimer's drug next week (Video)bizjournals.com
- MBiogen's stock rallies 11% after FDA accepts application for experimental Alzheimer's drugmarketwatch.com
- BFDA Narrows Its Label on Biogen's Alzheimer's Drug a Month After Approving It3 min readbarrons.com
- BThe FDA Decision on Biogen's Alzheimer's Drug Is Almost Here. What Investors Need to Know.barrons.com
- BFDA Approves Eisai and Biogen's New Alzheimer's Therapy 1 min readbarrons.com
- MBiogen's stock rises on submission to FDA for Alzheimer's drug applicationmarketwatch.com